Star Rating for Biosimilars Act
- Last Action
- 4/27/2021
Actions
- 2021-04-27Referred to the Subcommittee on Health.
- 2021-04-26Referred to the Subcommittee on Social Security.
- 2021-04-26Referred to the Subcommittee on Health.
- 2021-04-26Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-26Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-26Introduced in House
- 2021-04-26Introduced in House
CRS Summary
As of 2021-04-26 (00)
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
Cosponsors (1)
- Bob Gibbs (R-OH)
Subjects
- Health care costs and insurance
- Health care coverage and access
- Health care quality
- Health programs administration and funding
- Medicare
- Performance measurement
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.